Search Result

Results for "

MIA PaCA-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Apoptosis (9) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (1) c-Met/HGFR (2) Caspase (1) CDK (2) DNA/RNA Synthesis (3) EGFR (2) ERK (1) Ferroptosis (1) Fluorescent Dye (1) G-quadruplex (3) Glutathione Peroxidase (1) GSK-3 (1) HDAC (1) Hedgehog (1) IGF-1R (1) JAK (1) Lactate Dehydrogenase (2) MEK (3) Mitochondrial Metabolism (2) Molecular Glues (1) mTOR (1) NAMPT (1) NEKs (1) Oxidative Phosphorylation (2) p38 MAPK (1) PARP (1) PDGFR (2) Phosphatase (2) Phosphodiesterase (PDE) (2) PI3K (3) PROTACs (1) Raf (2) Ras (16) Reactive Oxygen Species (1) SHP2 (1)
By Research Areas:	Cancer (54) Endocrinology (1) Infection (2) Inflammation/Immunology (2) Neurological Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146459

Akt1-IN-1	Akt	Cancer
Akt1-IN-1 (compound 5b) is a potent and selective Akt1 inhibitor with an IC₅₀ value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 µM). Akt1-IN-1 can be used for researching anticancer .

HY-155065

SB-1295	Reactive Oxygen Species Apoptosis CDK	Cancer
SB-1295 is an orally active CDK9/T1 inhibitor (IC₅₀=0.17 μM). SB-1295 shows antiproliferative activity in HCT 116 and MIA PaCa-2 cells. SB-1295 also induces MIA PaCa-2 cell death by inducing intracellular ROS production, reducing mitochondrial membrane potential and inducing apoptosis. SB-1295 has the potential to study cancer .

HY-P2698

1-Alaninechlamydocin	HDAC Apoptosis	Cancer
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent HDAC inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

HY-149607

SHP2-IN-22	SHP2	Cancer
SHP2-IN-22 is SHP2 allosteric inhibitor with an IC₅₀ value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research .

HY-142946

KRAS G12C inhibitor 44	Ras	Cancer
KRAS G12C inhibitor 44 (compound 54) is a potent and orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC₅₀s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo .

HY-146543

KRAS inhibitor-13	Ras	Cancer
KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC₅₀s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146533

KRAS inhibitor-12	Ras	Cancer
KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC₅₀s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146544

KRAS inhibitor-14	Ras	Cancer
KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC₅₀s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146545

KRAS inhibitor-15	Ras	Cancer
KRAS inhibitor-15 (compound 3-19) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.954 µM. KRAS inhibitor-15 shows p-ERK inhibition activities with IC₅₀s of 2.03, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-15 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146546

KRAS inhibitor-16	Ras	Cancer
KRAS inhibitor-16 (compound 3-11) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.457 µM. KRAS inhibitor-16 shows p-ERK inhibition activities with IC₅₀s of 3.06, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-16 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146475

KRAS inhibitor-17	Ras	Cancer
KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC₅₀ of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC₅₀s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146476

KRAS inhibitor-18	Ras	Cancer
KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC₅₀ of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC₅₀s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-D2380

H2S probe 1	G-quadruplex	Cancer
H2S probe 1 (compound 1NND) is a derivative of nitrobenzoxadiazole (NBD) with antitumor activity. H2S probe 1 is cytotoxic to human pancreatic cancer cell MIA PaCa-2 (IC₅₀=77.9 nM) and has a high affinity for human telomeric G-quadruplex (G4) (K_d=1.72 μM). H2S probe 1 can be used in cancer research .

HY-146537

KRAS G12C inhibitor 47	Ras	Cancer
KRAS G12C inhibitor 47 (compound 8-1-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.172 µM. KRAS G12C inhibitor 47 shows p-ERK inhibition activities with IC₅₀s of 0.046, 69.8 µM in MIA PaCA-2, A549 cells, respectively. KRAS G12C inhibitor 47 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-144310

DX3-213B	Oxidative Phosphorylation Mitochondrial Metabolism	Cancer
DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor (IC₅₀=3.6 nM). DX3-213B impairs ATP generation (IC₅₀=11 nM), and blocks MIA PaCa-2 cell growth (GI₅₀=11 nM). DX3-213B is used for the research of the pancreatic cancer .

HY-16967

MM41	G-quadruplex	Cancer
MM41 is a potent stabilizer of human telomeric and gene promoter DNA quadruplexes. MM41 is potently against the MIA PaCa-2 pancreatic cancer cell line with IC₅₀ value of <10 nM .

HY-155356

YN14	PROTACs Ras	Cancer
YN14 is a KRASG12C proteolysis targeting chimera (PROTAC). YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG). YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth. YN14 leads to tumor regression with tumor growth inhibition (TGI%) rates more than 100 % in the MIA PaCa-2 xenograft model.

HY-13323

CX-5461 Maximum Cited Publications 32 Publications Verification	DNA/RNA Synthesis	Cancer
CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC₅₀s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .

HY-144311

OXPHOS-IN-1	Oxidative Phosphorylation Mitochondrial Metabolism	Cancer
OXPHOS-IN-1 (compound 2) is a oxidative phosphorylation (OXPHOS) inhibitor. OXPHOS-IN-1 inhibits the cells growth of MIA PaCa-2 and BxPC-3 cells with IC₅₀s of 2.34 μM and 13.82 μM, respectively .

HY-156549

KRAS G12C inhibitor 61	ERK Ras	Cancer
KRAS G12C inhibitor 61 (Example 3) inhibits phospho-ERK 1/2 in MIA PaCa-2 cells with an IC₅₀ value of 9 nM. KRAS G12C inhibitor 61 can be used for research of pancreatic, colorectal, and lung cancers .

HY-13323A

CX-5461 dihydrochloride Maximum Cited Publications 32 Publications Verification	DNA/RNA Synthesis	Cancer
CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC₅₀s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC₅₀ ≥25 μM).

HY-153090

Transketolase-IN-4	Bacterial	Infection Cancer
Transketolase-IN-4 is a potent transketolase inhibitor (IC₅₀=3.9 μM). Transketolase-IN-4 inhibits tumor cell proliferation of SW620, LS174T, and MIA PaCa-2. Transketolase-IN-4 is a possible Mycobacterium tuberculosis DXS inhibitor, with an IC50 value of 114.1 μM .

HY-13323R

CX-5461 (Standard)	DNA/RNA Synthesis	Cancer
CX-5461 (Standard) is the analytical standard of CX-5461. This product is intended for research and analytical applications. CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .

HY-123597

NSC 109555 DDUG; NCI C04808	Others	Cancer
NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC₅₀=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC₅₀ values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC₅₀=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.

HY-162873

MEK/RAF-IN-1	MEK Raf	Cancer
MEK/RAF-IN-1 (Compound 16b) is an inhibitor of both MEK and RAF. It shows potent inhibition with IC₅₀ values of 28 nM for MEK1, and 3 nM each for BRAF and BRAFV600E. MEK/RAF-IN-1 demonstrates significant antitumor activity, effectively inhibiting cell proliferation in vitro against MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Additionally, it inhibits tumor growth in xenograft mouse models of colorectal cancer .

HY-159577

Nic-15	PI3K mTOR Akt	Cancer
Nic-15 (compound 4n) is an anti-constrictive agent used to antagonize the hypovascularity of pancreatic tumors. The hypovascularity allows cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop drug resistance. Nic-15 can regulate the PI3K/Akt/mTOR pathway and alleviate ER stress induced by Gemcitabine (HY-17026). Nic-15 can significantly inhibit the migration and colony formation of MIA PaCa-2 and PANC-1 pancreatic cancer cells. The combination of Nic-15 and Gemcitabine can effectively solve the problem of pancreatic tumor resistance. In an in vivo xenograft model, Nic-15 can significantly enhance the efficacy of Gemcitabine .

HY-161858

EpskA21	PI3K Akt Apoptosis	Cancer
EpskA21 is an inhibitor for PI3K/AKT signaling pathway, and inhibits the proliferation of cancer cells MCF-7, A549, MIA-PaCa-2, Panc-1 and HepG2, with IC₅₀ of 1.3-7.24 μM. EpskA21 inhibits the cell migration, arrests the cell cycle at G2/M (MCF-7) and S (MIA-PaCa-2) phase, and induces apoptosis in MCF-7 and MIA-PaCa-2. EpskA21 causes the mitochondrial dysfunction .

HY-114189

GW284543 UNC10225170	MEK	Cancer
GW284543 (UNC10225170) is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein .

HY-114189A

GW284543 hydrochloride UNC10225170 hydrochloride	MEK	Cancer
GW284543 (UNC10225170) hydrochloride is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein .

HY-159511

Hedgehog IN-7	Hedgehog	Cancer
Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .

HY-122152

Spiclomazine hydrochloride APY-606; Clospirazine hydrochloride	Ras	Neurological Disease Cancer
Spiclomazine hydrochloride (APY-606) is an antipsychotic and antitumor agent. Spiclomazine hydrochloride inhibits KRas. Spiclomazine hydrochloride induces cancer cell apoptosis .

HY-161320

EGFR-IN-105	EGFR Apoptosis	Cancer
EGFR-IN-105 (Compound 5b) is an EGFR2 inhibitor with an IC₅₀ value of 0.68 μM. EGFR-IN-105 exhibits anticancer activity and can induce apoptosis in cancer cells, which is used in the research of pancreatic cancer .

HY-161425

Antitumor agent-149	Apoptosis	Cancer
Antitumor agent-149 (Compound 3) is an analogue of Echinomycin (HY-106101). Antitumor agent-149 inhibits HIF-1α-mediated transcription. Antitumor agent-149 induces cancer cell apoptosis. Antitumor agent-149 inhibits tumor growth in SW620 xenograft mice model .

HY-162763

FLQY2	Apoptosis	Cancer
FLQY2 is a camptothecin analog that exhibits outstanding antitumor efficacy against various solid tumors. FLQY2 possesses both in vitro and in vivo anti-pancreatic cancer activity, inhibiting cell proliferation, colony formation, inducing apoptosis, and causing cell cycle arrest at nanomolar concentrations .

HY-112089

Naporafenib 3 Publications Verification LXH254	Raf p38 MAPK Bcr-Abl	Cancer
Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC₅₀ values of 0.072 and 0.21 nM against CRAF and BRAF, respectively .

HY-149511

MET/PDGFRA-IN-2	c-Met/HGFR Apoptosis PDGFR	Cancer
MET/PDGFRA-IN-2 (compound 8h) is a MET and PDGFRA protein inhibitor. MET/PDGFRA-IN-2 induces cell apoptosis. MET/PDGFRA-IN-2 inhibits proliferation of MET-positive cells (IC₅₀s: 9.7, 6.1, 12.0, 11.5, 8.6, 34.4 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .

HY-149510

MET/PDGFRA-IN-1	c-Met/HGFR Apoptosis PDGFR	Cancer
MET/PDGFRA-IN-1 (compound 8c) is a MET and PDGFRA protein inhibitor (IC₅₀: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC₅₀s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively) .

HY-162629

LDHA-IN-7	Lactate Dehydrogenase	Cancer
LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC₅₀s of 72 nM and 1.2 Μm, respectively .

HY-112776

BN82002	Phosphatase	Cancer
BN82002 is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC₅₀ values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .

HY-112776A

BN82002 hydrochloride 1 Publications Verification	Phosphatase	Cancer
BN82002 hydrochloride is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC₅₀ values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 hydrochloride displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .

HY-137046

Nek2-IN-4	NEKs	Cancer
Nek2-IN-4 is a potent NEK2 inhibitor with an IC₅₀ value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer .

HY-154313

Spiclomazine Clospirazine	Ras	Cancer
Spiclomazine (Clospirazine) is a potent mutant KRAS(G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models .

HY-155874

ZNL-05-044	CDK	Cancer
ZNL-05-044 is a CDK11 inhibitor with an IC₅₀s of 0.23 μM and 0.27 μM against CDK11A and CDK11B, respectively (NanoBRET assay). ZNL-05-044 leads to G2/M cell cycle arrest and impairs RNA splicing .

HY-120966

NCX 2121	Others	Inflammation/Immunology
NCX 2121 (NO-indomethacin) is an anti-inflammatory agent. NCX 2121 inhibits PaCa-2 cells growth witn an IC₅₀ of 82 μM .

HY-108436

Deltazinone 1	Phosphodiesterase (PDE)	Cancer
Deltazinone 1, a pyrazolopyridazinone, is a highly selective PDEδ inhibitor with a K_D of 8 nM. Deltazinone 1 inhibits the PDEδ-Ras interaction. Deltazinone 1 shows a dose-dependent inhibitory response on proliferation in oncogenic KRas-dependent cell lines .

HY-147838

Nampt-IN-9	NAMPT	Cancer
Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .

HY-141477

RM-018	Ras	Cancer
RM-018 is a potent, functionally distinct tricomplex KRAS ^G12C active-state inhibitor. RM-018 retains the ability to bind and inhibit KRAS ^G12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRAS ^G12C .

HY-148012

SOP1812 QN-302	G-quadruplex	Cancer
SOP1812 (QN-302) is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with K_D values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer .

HY-145926

MRTX0902	Ras	Cancer
MRTX0902 is an orally active and potent SOS1 inhibitor with an IC₅₀ of 46 nM (WO2021127429A1; Example 12-10) .

HY-149076

hGAPDH-IN-1	Others	Cancer
hGAPDH-IN-1, a 3-bromo-4,5-dihydroisoxazole derivative, is a specific and potent hGAPDH covalent inhibitor. hGAPDH-IN-1 reduces cancer cell growth in different pancreatic cancer cell lines.

Cat. No.	Product Name	Type

HY-D2380

H2S probe 1	Fluorescent Dyes/Probes
H2S probe 1 (compound 1NND) is a derivative of nitrobenzoxadiazole (NBD) with antitumor activity. H2S probe 1 is cytotoxic to human pancreatic cancer cell MIA PaCa-2 (IC₅₀=77.9 nM) and has a high affinity for human telomeric G-quadruplex (G4) (K_d=1.72 μM). H2S probe 1 can be used in cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P2698

1-Alaninechlamydocin	HDAC Apoptosis	Cancer
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent HDAC inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

Cat. No.	Product Name		Classification

HY-159511

Hedgehog IN-7		Azide
Hedgehog IN-7 (Compound 8g), a purine derivative, acts as an inhibitor of Hedgehog, capable of reducing the expression of Hedgehog genes and inhibiting Hedgehog signaling. Hedgehog IN-7 has significant cytotoxicity and selectivity towards the Hedgehog pathway-dependent pancreatic cancer cell Mia-PaCa-2 cells and can be used in the research of pancreatic cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MIA PaCA-2

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Click Chemistry

Natural
Products